Enlivex Therapeutics R&D Ltd
USPTO PatentsView assignee record - 15 granted patents across 8 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Enlivex ranks #18,586 of 49,997 tracked US assignees by granted-patent volume, with 15 patents across 8 technology areas.
- #18,586
- of 49,997 US assignees by volume
- Top 16%
- by Innovation Score (48.5/100)
- 14.9
- avg claims per patent
- +500%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R18586 · Foreign Corporation #18,586 · 15 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
- GRANTS-MICRO 15 grants
- MID-PACK #18,586/49,997
- PHOTO-FINISH Emcure Pharmaceuticals
- CPC-NARROW A61P · 8 areas
- INNOV-PAR 48.5/100
- CLAIMS-RICH 14.9 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-SURGE +500% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Emcure Pharmaceuticals Limited (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Enlivex’s 48.5 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Enlivex
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Enlivex Therapeutics… · this assignee
Enlivex Therapeutics… · this assignee
49 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Enlivex's Innovation Score is 48.5/100 (top 16% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Enlivex?
Each dot is one of Enlivex’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Enlivex’s own 14.9 claims/patent is ABOVE the 11.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Enlivex's grants concentrate
Enlivex Therapeutics R&D Ltd is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (4 grants) versus a trough of 1 in 2017. By volume, Enlivex sits between Emcure Pharmaceuticals Limited and Essentium Ipco, LLC.
Enlivex's three-year grant acceleration
Enlivex Therapeutics R&D Ltd shows 9 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Enlivex's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Emcure Pharmaceut…
Emcure Pharmaceuticals Limited
15 patents
- Emergex Vaccines…
Emergex Vaccines Holding Limited
15 patents
- Eneos Materials
Eneos Materials Corporation
15 patents
- Enermax Technology
Enermax Technology Corporation
15 patents
- EOS Imaging
EOS Imaging
15 patents
- Erasmus Universit…
Erasmus University Medical Center
15 patents
- Erco
Erco GMBH
15 patents
- Essentium Ipco
Essentium Ipco, LLC
15 patents
- Enlivex Therapeut… ◀
Enlivex Therapeutics R&D Ltd
15 patents
What this shows Enlivex holds 15 patents at rank #18,571, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Enlivex
By rank, the assignees closest to #18,571 in granted patent volume.
- Emcure Pharmaceuticals Limited #18,567 · 15 patents
- Emergex Vaccines Holding Limited #18,568 · 15 patents
- Eneos Materials Corporation #18,569 · 15 patents
- Enermax Technology Corporation #18,570 · 15 patents
- EOS Imaging #18,572 · 15 patents
- Erasmus University Medical Center #18,573 · 15 patents
- Erco GMBH #18,574 · 15 patents
- Essentium Ipco, LLC #18,575 · 15 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Enlivex's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Enlivex's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
49 Top 16% higher than 84% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 6.7% |
| 2018 | 1 | 6.7% |
| 2020 | 1 | 6.7% |
| 2021 | 2 | 13.3% |
| 2022 | 4 | 26.7% |
| 2023 | 3 | 20.0% |
| 2024 | 2 | 13.3% |
| 2025partial year | 1 | 6.7% |
Which technologies does Enlivex Therapeutics R&D Ltd patent most?
Top 8 of 8 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Enlivex Therapeutics R&D Ltd's patent record in context - here's where to go next.
- Enlivex Therapeutics R&D Ltd's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #18,586 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Enlivex Therapeutics R&D Ltd against Emcure Pharmaceuticals Limited, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 48.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.